Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/17476348.2021.1856659 http://scihub22266oqcxt.onion/10.1080/17476348.2021.1856659 33249945!7869432!33249945     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33249945&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Expert+Rev+Respir+Med 2021 ; 15 (4): 543-552 Nephropedia Template TP {{tp|p=33249945|t=2021. Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study |pdf=|usr=}}{{33249945}} gab.com Text Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study JO: Expert Rev Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=33249945 #FOAvip OBJECTIVES: To explore the efficacy of corticosteroid treatment in patients with severe COVID-19 pneumonia and the association between corticosteroid use and patient mortality. METHODS: A retrospective investigation was made on the medical records of the patients with severe and critical patients with COVID-19 pneumonia from January to February 2020. First, the patients who received corticosteroid treatment were compared with patients without given corticosteroid treatment. Then, a propensity score matching method was used to control confounding factors. Cox survival regression analysis was used to evaluate the effect of corticosteroid therapy on the mortality of severe and critical patients with COVID-19. RESULTS: A total of 371 severe and critical patients were included in our analyses. Two hundred and enine patients were treated with corticosteroid therapy. Most of them were treated with methylprednisolone (197[94.3%]). The median corticosteroid therapy was applied 3 (IQR 2-6) days after admission, 13 (IQR 10-17) days after symptoms appeared. Temperature on admission (OR = 1.255, [95%CI 1.021-1.547], p = 0.032), ventilation (OR = 1.926, [95%CI 1.148-3.269], p = 0.014) and ICU admission (OR = 3.713, [95%CI 1.776-8.277], p < 0.001) were significantly associated with corticosteroids use. After PS matching, the cox regression survival analysis showed that corticosteroid use was significantly associated with a lower mortality rate (HR = 0.592, [95%CI 0.406-0.862], p = 0.006). CONCLUSION: Corticosteroid therapy use in severe and critical patients with COVID-19 pneumonia leads to lower mortality but may cause other side effects. Corticosteroid therapy should be used carefully. Twit Text FOAVip Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study ????Expert Rev Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=33249945 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33249945 #FOAvip English Wikipedia <ref>{{Cite pmid|33249945}}</ref> Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study #MMPMID33249945 Chen Q; Song Y; Wang L; Zhang Y; Han L; Liu J; Yang M; Ma J; Wang T Expert Rev Respir Med 2021[Apr]; 15 (4): 543-552 PMID33249945show ga OBJECTIVES: To explore the efficacy of corticosteroid treatment in patients with severe COVID-19 pneumonia and the association between corticosteroid use and patient mortality. METHODS: A retrospective investigation was made on the medical records of the patients with severe and critical patients with COVID-19 pneumonia from January to February 2020. First, the patients who received corticosteroid treatment were compared with patients without given corticosteroid treatment. Then, a propensity score matching method was used to control confounding factors. Cox survival regression analysis was used to evaluate the effect of corticosteroid therapy on the mortality of severe and critical patients with COVID-19. RESULTS: A total of 371 severe and critical patients were included in our analyses. Two hundred and enine patients were treated with corticosteroid therapy. Most of them were treated with methylprednisolone (197[94.3%]). The median corticosteroid therapy was applied 3 (IQR 2-6) days after admission, 13 (IQR 10-17) days after symptoms appeared. Temperature on admission (OR = 1.255, [95%CI 1.021-1.547], p = 0.032), ventilation (OR = 1.926, [95%CI 1.148-3.269], p = 0.014) and ICU admission (OR = 3.713, [95%CI 1.776-8.277], p < 0.001) were significantly associated with corticosteroids use. After PS matching, the cox regression survival analysis showed that corticosteroid use was significantly associated with a lower mortality rate (HR = 0.592, [95%CI 0.406-0.862], p = 0.006). CONCLUSION: Corticosteroid therapy use in severe and critical patients with COVID-19 pneumonia leads to lower mortality but may cause other side effects. Corticosteroid therapy should be used carefully. |*COVID-19 Drug Treatment[MESH] |Adrenal Cortex Hormones/*therapeutic use[MESH] |Aged[MESH] |COVID-19/mortality[MESH] |Female[MESH] |Hospitalization[MESH] |Humans[MESH] |Male[MESH] |Methylprednisolone/*therapeutic use[MESH] |Middle Aged[MESH] |Propensity Score[MESH] |Retrospective Studies[MESH] |Survival Rate[MESH]Corticosteroids treatment in severe patients with COVID-19: a propensi(epmc).pdf DeepDyve Pubget Overpricing